In this week’s notable new products roundup, Tate’s Bake Shop ventures into a new format, GoodPop expands its partnership ...

Eli Lilly's (LLY) cease-and-desist letter is dismissed by weight loss drug compounder, OrderlyMeds. Read more here.

Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the ...

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

Secretary Robert F. Kennedy Jr. said he is considering a “regulatory framework” for Medicare and Medicaid to cover GLP-1 ...

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic benefits through a unique fat-blocking mechanism. However, its high ...

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic ...

A retrospective study found that women who took a GLP-1 drug for obesity were more likely to be diagnosed with acne vulgaris ...

GLP-1 drugs are blockbuster medications for weight loss and Type 2 diabetes. Now doctors are trying them for lymphedema, ...

But this is just the start. GLP-1 drugs (specifically Novo Nordisk’s Ozempic, Rybelsus and Wegovy and Eli Lilly’s Mounjaro ...